Definiens Expands Stereology Capabilities for Quantitative Digital Pathology
Stereology complements the unique combination of flexibility and ease-of-use that makes Definiens Tissue Studio® the leading solution for analyzing histological samples. With the latest release of Definiens Tissue Studio 3.5, systematic random sampling is now available out of the box.
High productivity through end-to-end automation is achieved by combining stereological methods with Definiens' automated and precision detection of structure and morphology in heterogeneous tissue. This significantly reduces user interaction and analysis time and delivers unbiased and detailed readouts at the same time. Alternatively, semi-automatic or manual stereology workflows can be applied wherever appropriate.
For three dimensional measurements, Definiens also offers automated co-registration of serial tissue sections. Definiens stereology solutions are compatible with all major slide image file formats on the market and work with both bright field and fluorescence image data.
"Stereological methods are a long established approach to obtaining quantitative data about three-dimensional features from two dimensional tissue sections," says Thomas Heydler, CEO, Definiens. "Definiens' offerings in image and data analysis provide biomedical professionals with tools to significantly accelerate workflows and retrieve unparalleled insights from tissue samples."
Visit Definiens at the USCAP's industry exhibition, booth number 807, Vancouver, Canada, from March 17-23, 2012.
Definiens is the leading provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, tissue diagnostics and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources, generating new knowledge and supporting better decisions in research, diagnostics and therapy. By automating analysis workflows, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists with deeper insights and faster results, increasing speed to market and ROI. Harnessing the power of image intelligence, Definiens makes possible new fields of research, supports the development of personalized medicine and aims to significantly improve the quality of patients' lives.
Definiens is headquartered in Munich, Germany, and has offices throughout the United States.